ancer society. Last Access date: 20 July 2019. Available: https://www.cancer.org/es/.
Baum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., … Wester, H.-J. (2016). 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. Journal of Nuclear Medicine, 57(7), 1006-1013. doi:10.2967/jnumed.115.168443
Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., … Böning, G. (2015). Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 43(1), 42-51. doi:10.1007/s00259-015-3174-7
[+]
ancer society. Last Access date: 20 July 2019. Available: https://www.cancer.org/es/.
Baum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., … Wester, H.-J. (2016). 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. Journal of Nuclear Medicine, 57(7), 1006-1013. doi:10.2967/jnumed.115.168443
Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., … Böning, G. (2015). Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 43(1), 42-51. doi:10.1007/s00259-015-3174-7
Emmett, L., Willowson, K., Violet, J., Shin, J., Blanksby, A., & Lee, J. (2017). Lutetium177PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. Journal of Medical Radiation Sciences, 64(1), 52-60. doi:10.1002/jmrs.227
Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C., & Eiber, M. (2017). 177Lu-PSMA Radioligand Therapy for Prostate Cancer. Journal of Nuclear Medicine, 58(8), 1196-1200. doi:10.2967/jnumed.117.191023
Grimm, P., Billiet, I., Bostwick, D., Dicker, A. P., Frank, S., Immerzeel, J., … Langley, S. (2012). Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International, 109, 22-29. doi:10.1111/j.1464-410x.2011.10827.x
Karaiskos, P., Papagiannis, P., Sakelliou, L., Anagnostopoulos, G., & Baltas, D. (2001). Monte Carlo dosimetry of the selectSeed 125I interstitial brachytherapy seed. Medical Physics, 28(8), 1753-1760. doi:10.1118/1.1384460
Monte Carlo team, “MCNP6TM – User's Manual, Version 6.1.1beta”, Los Álamos National Laboratory, LA-CP-14-00745, Rev. 0, June 2014. Materialise. Mimics Medical 17.0 Reference Guide.
Rahbar, K., Afshar-Oromieh, A., Jadvar, H., & Ahmadzadehfar, H. (2018). PSMA Theranostics: Current Status and Future Directions. Molecular Imaging, 17, 153601211877606. doi:10.1177/1536012118776068
Scarpa, L., Buxbaum, S., Kendler, D., Fink, K., Bektic, J., Gruber, L., … Virgolini, I. (2017). The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. European Journal of Nuclear Medicine and Molecular Imaging, 44(5), 788-800. doi:10.1007/s00259-016-3609-9
Skowronek, J. (2017). Current status of brachytherapy in cancer treatment – short overview. Journal of Contemporary Brachytherapy, 9(6), 581-589. doi:10.5114/jcb.2017.72607
Stock, R. G., Stone, N. N., Cesaretti, J. A., & Rosenstein, B. S. (2006). Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. International Journal of Radiation Oncology*Biology*Physics, 64(2), 527-533. doi:10.1016/j.ijrobp.2005.07.981
[-]